AllSides Balanced Search reveals information and ideas from all sides of the political spectrum so you can get the full picture.
Aug 01 2020
Background
The Basics of ‘Medicare for All’
It’s possible you’ve tuned out when the Democrats running for president have tussled over “Medicare for all.” But now that Bernie Sanders, who introduced the Medicare for All Act in the Senate, is ascending in the nominating contest, it’s a good time to take a closer look at what it would mean for the health system, your health insurance and finances, and the federal budget.
Here’s our
New York Times (News)
Aug 29 2023
News
What’s next in Medicare price negotiation
The medications announced on Tuesday target highly common diseases in the U.S., such as heart disease, heart failure, rheumatoid arthritis and diabetes. The selection included insulin drug NovoLog, blood thinner Eliquis, antidiabetic Jardiance and leukemia drug Imbruvica, as well as a more unanticipated pick: Stelara, which is used to treat Crohn’s disease. The drugs chosen for initial
The Hill
Aug 30 2023
News
Medicare should negotiate with drugmakers. But not set prices
A quirk of American law long barred Medicare, the public-health insurer for the elderly, from negotiating with drug firms over prices. Even as the National Health Service in Britain and other government procurers haggled with companies to bring costs down, one of the world’s biggest spenders on drugs was forced to be a price-taker. Americans, meanwhile, spend more than twice as much on
The Economist
Aug 01 2020
Background
Medicare-for-All Is Not Medicare, and Not Really for All. So What Does It Actually Mean?
Ritchard Jenkins reached into the black computer bag he keeps near his workstation at Graceful Touch Barber and Beauty Salon and rifled through medical papers, pulling out an envelope buried deep at the bottom.
It was an unopened medical bill for $971.78, now 17 months overdue, that he had put out of sight and out of mind. Another unpaid bill from May for $447.13 rested in a nearby
ProPublica
Aug 30 2023
News
Medicare reveals first drugs up for price cuts
Drugmakers attacked the Inflation Reduction Act on Tuesday as Medicare unveiled the first drugs to face price caps under the law. The drugs include the blood thinner Eliquis, diabetes treatment Jardiance and eight other medications. The negotiation process, authorized last year, caps decades of debate over whether the federal government should be allowed to haggle with pharmaceutical companies
Arkansas Democrat-Gazette
Aug 29 2023
News
Unexpected drugs make first round of Medicare negotiations
The Centers for Medicare and Medicaid Services (CMS) has officially named the first 10 drugs chosen for price negotiation under the Inflation Reduction Act (IRA), and while most picks were anticipated, a few of the medicines named on Tuesday came as something of a surprise. The IRA was highly specific with which Medicare-covered drugs could be eligible for negotiation, as well as which ones
The Hill
Aug 01 2020
Background
Medicare for all: fears and facts
Each candidate has their own way to fix what ails health insurance. Everyone claimed “Medicare” at the heart of their strategy. Sen. Bernie Sanders (D-Vt.) and Sen. Elizabeth Warren (D-Mass.) urged sweeping reform, while former Vice President Joe Biden and others advocated tinkering at the margins, stoking fear of big change.
What does it all mean?
After the first Democratic
The Hill
Aug 29 2023
News
Biden Administration Reveals First 10 Drugs For Medicare Price Negotiation
The federal government just identified the first 10 medications that will be subject to direct price negotiations with manufacturers, as part of a major new initiative to reduce prescription drug costs in Medicare.
The list includes a pair of widely used blood thinners, Eliquis and Xarelto, as well as the cancer therapy Imbruvica. It also includes Farxiga, Jardiance and Januvia, all of
HuffPost
Sep 01 2023
News
How a Republican president could affect Medicare drug negotiations
A future Republican president who opposes Medicare drug price negotiations likely couldn't dismantle or ignore the process but could have some regulatory discretion to seek lower price cuts, experts told Axios.
Why it matters: Giving Medicare the ability to negotiate drug prices was a signature achievement for President Biden. Republicans, meanwhile, have long opposed Medicare
Axios